Form 4: Raymond Dwek Executes Share Tracking Awards Under 10b5-1 Plan

Director Raymond Dwek exercised share tracking awards of United Therapeutics Corporation under a pre-arranged Rule 10b5-1 trading plan, resulting in cash settlement.

Summary

• Raymond Dwek, a director of United Therapeutics Corporation, executed share tracking awards on April 22, 2024.
• The transactions were carried out under a pre-arranged Rule 10b5-1 trading plan established on November 27, 2023.
• 3,000 share tracking awards were exercised at a price of $88.03, resulting in a cash settlement.
• Additionally, 3,000 common stock units were disposed of at $234.06.
• Following the reported transactions, Dwek beneficially owns 1,750 shares of common stock.
• The share tracking awards are non-dilutive cash-settled stock appreciation rights and cannot be converted into common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports routine transactions under a pre-existing trading plan. There are no indications of unusual or concerning activity.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, indicating a planned and transparent approach to managing equity.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• The transactions provide transparency to shareholders regarding insider trading activities.

Key Dates